STAT3 and pancreatic neoplasm: Our results support that Lip-FLLL32 could be a promising therapeutic agent sensitizing pancreatic cancer cells to chemo/radio-therapy via efficient delivery of FLLL32 and then inhibition of STAT3 in vivo.